How patients can be assured of consistent medical cannabis quality will be explored at an event next week examining the evidence, prescribing and patient care behind cannabis treatment.
Silvia von Pistor, chief innovation officer at Canify, a German pharmaceutical company specialising in medical cannabis, will join a discussion on whether Europe needs shared quality standards.
The panel brings together specialists in manufacturing, regulation and product standards to examine how medicines are produced and checked before reaching patients.
Von Pistor has more than 20 years’ experience in pharmaceutical research and development, including developing medicines and securing product approvals.
Speaking with Cannabis Health ahead of the event, she identified bringing “reliable quality” to patients as a priority.
The discussion will consider consistency between batches and how clinicians choose a suitable replacement when a patient’s prescribed product is unavailable.
Joining her will be Ana Serrato, chair of ASTM International’s cannabis human health subcommittee; Tjalling Erkelens, founder of Bedrocan; and Sita Schubert, general secretary of the European Medicinal Cannabis Association.
The Cannabis Health Symposium takes place at Mainhaus, Frankfurt, on 4 November. Tickets and the full programme are available here.
